The FDA is experiencing ongoing resource constraints impacting its ability to meet drug approval deadlines. Commissioner Marty Makary has proposed consolidations of administrative functions to improve efficiency amid staffing cuts following major layoffs across Health and Human Services. Recent drug application delays include KalVista Pharmaceuticals’ hereditary angioedema candidate and other notable biotech submissions. The agency’s resource challenges have drawn scrutiny as delays continue despite efforts to protect core scientific review groups.